OS4.4 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial

由 Pouessel, D, Mervoyer, A, Larrieu-Ciron, D, Cabarrou, B, Robert, M, Frenel, J, Olivier, P, Mounier, M, Cohen-Jonathan Moyal, E
發表在 Neuro Oncol (2019)

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref...

由 Frappaz, D., Meyronnet, D., Garin, G., Laigle-Donadey, F., Le Rhun, E., Bonneville-Levard, A., Frenel, J., Idbaih, A., Gourmelon, C., Chinot, O.
發表在 Neuro Oncol (2016)

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

由 Loussouarn, D, Campion, L, Sagan, C, Frenel, J-S, Dravet, F, Classe, J-M, Pioud-Martigny, R, Berton-Rigaud, D, Bourbouloux, E, Mosnier, J-F, Bataille, F-R, Campone, M
出版 2008

P04.12 Characteristics of IDH-mutant gliomas with non-canonical IDH mutations

由 Poetsch, L, Dehais, C, Frénel, J, Siegfried, A, Lacomme, S, Seizeur, R, Larrieu-Ciron, D, Cappellen, D, Loussouarn, D, Ferec, C, Eimer, S, Carpentier, C, Sanson, M, Delattre, J, Figarella-Branger, D, Ducray, F, Bronnimann, C
發表在 Neuro Oncol (2019)

P11.08 Defining EGFR amplification status for clinical trial inclusion

由 French, P, Eoli, M, Sepulveda, J, de Heer, I, Kros, J M, Walenkamp, A, Frenel, J, Franceschi, E, Clement, P, Weller, M, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, van den Bent, M
發表在 Neuro Oncol (2019)

OS4.3 Feasibility and benefit of Molecular Profiling to Guide Enrollment of Patients with Recurrent Gliomas in Early Phase Trials

由 Baldini, C, Younan, N, Castanon Alvarez, E, Bahleda, R, Hollebecque, A, Dhermain, F, Ammari, S, Alentorn, A, Dumont, S, Frenel, J, Di Stefano, A, Bielle, F, Hoang-Xuan, K, Delattre, J, Soria, J, Sanson, M, Idbaih, A, Massard, C, Touat, M
發表在 Neuro Oncol (2019)